Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

scientific article published on 28 November 2020

Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41409-020-01155-Z
P698PubMed publication ID33249424

P50authorJohan MaertensQ89490552
Myriam LabopinQ89534568
Arnon NaglerQ89534579
Gerard SociéQ90009154
Annalisa PaviglianitiQ96054868
Edouard ForcadeQ103045566
Anne HuynhQ114324317
Igor W BlauQ114426815
Claude Eric BulaboisQ63384859
Mohamad MohtyQ86836425
Patrice ChevallierQ87734444
Eric DeconinckQ87979975
Didier BlaiseQ88013295
P2093author name stringPatrice Ceballos
Pascal Turlure
Bruno Lioure
Gaelle Guillerm
P2860cites workTailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetilQ88099530
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic TransplantationQ91179887
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialQ93086096
Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findingsQ34363323
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportQ34474243
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationQ35571053
Frailty models for survival dataQ36893595
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysisQ36920445
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Q38179975
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.Q40396484
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.Q40843566
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkQ42149848
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.Q42269523
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.Q43102402
MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblingsQ43169783
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host diseaseQ43241161
Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donorsQ43283506
Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipientsQ44216325
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemiaQ44237334
Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow TransplantationQ44243900
Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantationQ45001838
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantationQ45010717
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblingsQ45132133
Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD.Q45979461
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.Q51759367
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.Q52896167
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donorsQ70051817
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantationQ72419264
Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects testsQ77977077
Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantationQ80694725
P577publication date2020-11-28
P1433published inBone Marrow TransplantationQ4941523
P1476titleComparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT